GMDA News and Press, Gamida Cell Ltd. From 01/05/21

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in January: H.C. Wainwright Bioconnect 2021 Conference, ...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in ...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, Dece...

Gamida Cell ([[GMDA]] +4.6%) prices public offering of 8,125,000 common shares at a price of $8/share.Underwriters' have been granted overallotment option to purchase up to an additional 1,218,750 shares.The company intends to use the net proceeds to fund (i) the preparation of...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gr...

Gamida Cell (GMDA) announces the launch of a follow-on public offering of its ordinary shares.Underwriters' over-allotment is an additional 15% of shares. Net proceeds will be used to fund commercial launch of omidubicel, continued clinical development of product candidates, expansion of manu...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-...

Gainers: Arvinas (ARVN) +97%, Rubius Therapeutics (RUBY) +95%, AnPac Bio-Medical Science (ANPC) +67%, Veru (VERU) +46%, BioCardia (BCDA) +31%.Losers: Aerpio Pharmaceuticals (ARPO) -47%, SELLAS Life Sciences (SLS) -27%, Greenwich Life...

Gamida Cell (GMDA) fell 19% in premarket trading after saying FDA feedback means that the company won’t begin a rolling marketing submission by year’s end.The company now intends to submit a full marketing application for omidubicel in 2H of 2021, with potential U...

Aerpio Pharmaceuticals ARPO -43% after announcing results from Razuprotafib Glaucoma Phase 2 Trial.Greenwich LifeSciences (GLSI) -18%.Gamida Cell (GMDA) -18% on providing regulatory update on biologics license application for Omidubicel.Virgin Galactic Holdings SPCE -...